Subscribe to Insight Exchange on Apple Podcasts, Spotify and Amazon Music and Audible for the latest episodes.
In this episode of “Insight Exchange,” we explore the crucial role of Scope 3 emissions reduction in the pharmaceutical industry. Listen to L.E.K. Consulting experts Verena Ahnert and Max Cambras, who share their insights on the significance of Scope 3 emissions, the current state of commitments in pharma and how emissions reduction is both a strategic consideration and mutually beneficial to both pharma and the environment.
Key points/topics covered:
- Explanation of Scope 3 emissions and their importance in pharma
- The current state of Scope 3 commitments in the pharmaceutical industry
- Key drivers of Scope 3 emissions in pharma
- The strategic co-benefits of Scope 3 emissions reduction in the pharmaceutical industry
- The path to achieving strategic co-benefits through emissions reduction in pharma
Tune in for a deep dive into a pressing environmental issue that’s reshaping the pharma industry’s strategies and operations.
Interested in learning more? Read our Special Report, Scope 3 Emissions: A Strategic Imperative for Pharma Companies.
L.E.K. Consulting is a registered trademark of L.E.K. Consulting LLC. All other products and brands mentioned in this document are properties of their respective owners. © 2024 L.E.K. Consulting LLC
